Who we are

Sapient Therapeutics is a biopharmaceutical company focused on neuroscience drug discovery and early clinical development. Our lead asset (SAP021) has successfully completed initial Phase 1 studies.

Our leadership team is comprised of experienced neuroscience and cannabinoid medicine professionals. Together we are utilising the knowledge gained in cannabinoid development to bring new prescription medicines to patients suffering from serious diseases.

News

London, UK and Melbourne, Australia, 19 December 2023: Sapient Therapeutics Ltd (“Sapient Therapeutics”), a pioneering biopharmaceutical company specialising in neuroscience drug discovery ...

Read More

Sapient Therapeutics Ltd (“Sapient Therapeutics”), a pioneering biopharmaceutical company specialising in neuroscience drug discovery and early clinical development, is pleased to announce ...

Read More

Meet the Team

Giles MossChief Executive Officer

Led GW Pharmaceuticals European build out as General Manager Europe

Significant experience in orphan diseases, neurological disorders, and the commercialisation of cannabinoid medicines

Also at GW led ex-US Government and Public Affairs teams within the pharmaceutical sector

Whilst at UCB Head of CNS global marketing for Keppra® which grew to >1$bn in sales

Also at UCB held direct P&L responsibility for 24 countries in Asia and Europe

Read More

Rupert HaynesExecutive Chairman and R&D Director

Head of Global Marketing at GW Pharmaceuticals

Strategic commercial development of GW’s cannabinoid portfolio including pre-clinical drug candidate assessment

Commercial planning lead for the launch of Epidiolex® USA and EU

Led GW’s International Business Development with a focus on orphan disease indications

Oversight of Vimpat® at UCB, with >$1bn sales

Read More

Dr Andrew SaichChief Medical Officer

Created and led the GW Pharma International Medical organisation in preparation for the launch of Epidiolex®

Medical lead for the commercialisation of Sativex®

Member of the GW Pharma Clinical Development Committee and Corporate Drug Safety team

Led the GW global investigator initiated clinical studies program

Read More

Julian BrysonOperations & Investor Relations

Founded patented infection control technology development firm Sterilox Technologies

Sterilox technology used in sterilisation of endoscopes in 45% of NHS hospitals

Acquired by Cantel Medical Corp (now Steris).

Co-founded a Canadian based pharmaceutical multi-licensed platform technology development company

Read More

Dr Chris HayesHead of Intellectual Property

Ex Vice President & Global Head of IP at Jazz Pharmaceuticals, having joined Jazz on the acquisition of GW Pharmaceuticals plc

At GW Chris was VP of IP, responsible for developing and implementing an IP strategy to protect GW’s entire portfolio of cannabis based products

Read More

Grace PowellHead of Regulatory Affairs

Deep experience in Regulatory Affairs and cannabinoid medicines working at GW Pharmaceuticals

Worked on the filing of Epidiolex® in the US and led the regulatory team for the European filing of Epidyolex® with the EMA

Read More

Dr Venkat Goskonda Ph.D.Chief Scientific Officer

Venkat brings nearly 25 years of experience in drug development

A strong background in pharmaceutics, bio-pharmaceutics with a broad knowledge in FDA regulation

An expert in formulations having developed prescription products from concept through to commercialisation

Inventor on over 50 patents and patent applications and author of 7 publications in global Pharmaceutical Science journals

Read More

James GillespieHead of Project Management

Jim has more than 25 years’ of international experience in both private and government sectors encompassing sales, marketing, business development and the UK Department of International Trade

Ex-GW program leader for the EU & ROW commercialization of Epidyolex®, and re-commercialisation of Sativex® in the UK

Led GW’s Brexit readiness project ensuring regulatory, supply chain, finance, and legal preparedness irrespective of the final political solution

Ex-Jazz Pharma commercial program leader for the acquisition of GW and the divestment of Sunosi® to Axsome Therapeutics

Read More

Dr Emma CheethamIntellectual Property Attorney

Emma is a fully qualified European patent attorney with over 20 years’ experience in the pharmaceutical industry.

Previously Emma was IP Director at Jazz Pharmaceuticals, having joined Jazz on the acquisition of GW Pharmaceuticals plc.

At GW Emma was responsible for generating the patent portfolios for Epidiolex® and Sativex® in addition to IP-related activities such as trade mark filing, brand protection, licensing, and regulatory data protection activities.

Read More

Meet the Team

Scientific Advisory Board Members

Dr Johannes Roebers

Johannes Roebers has over 25 years leadership experience in site leadership, R&D leadership, major project leadership, strategy development, operations, engineering, regulatory affairs, clinical operations, and facilities across Germany, Canada, USA, and Ireland in small, medium, and large biopharmaceutical companies. 

He is the founder and General Manager of the Cilatus Group consulting companies which were recently acquired by Product Life Group.  Johannes was a cofounding executive of Prothena Bioscience Inc., South San Francisco, CA and served as Executive Vice President, Head of Operations, and Site Manager for Elan Pharmaceuticals, Dublin Ireland. 

Johannes also held senior leadership and management positions at Genentech, Biogen-IDEC, IDEC Pharmaceuticals, and Bayer.

Johannes enjoys developing fully integrated CMC development, regulatory, and manufacturing strategies. He is a thought leader in virtualization and outsourcing in the biopharmaceutical development and manufacturing area.

Johannes earned his Ph.D. in Chemical Engineering from Clemson University, South Carolina, USA and his Dipl.-Ing. Verfahrenstechnik from RWTH in Aachen, Germany.

Read More

Dr Philip McGuire

Philip McGuire is Professor of Psychiatry at the University of Oxford. He leads the Bioresource at NIHR Oxford Health Biomedical Research Centre and co-leads the Precision Psychiatry theme. He is Associate Director for Research & Development at Oxford Health NHS Foundation Trust and a Principal Investigator at the Wellcome Centre for Integrative Neuroimaging.

He studied medicine at the University of Edinburgh, neuroscience at Yale University and trained as a psychiatrist at the Maudsley Hospital in London. He was formerly an academic psychiatrist at the Institute of Psychiatry and the MRC Cyclotron Unit in London.

His research aims to understand the mechanisms underlying psychiatric disorders to inform the development of new treatments. He has published over 800 scientific papers and is a Highly Cited Researcher. He is a Fellow of the Academy of Medical Sciences, the Royal College of Psychiatrists, and the European Psychiatric Association.

Read More

Professor Finbar O’Callaghan

Finbar O'Callaghan is Professor of Paediatric Neuroscience at the UCL GOS Institute of Child Health, University College London and (Hon) Consultant Paediatric Neurologist at Great Ormond Street Hospital. He was President of the British Paediatric Neurology Association (BPNA) (2017-2020) and Secretary of the European Paediatric Neurology Association (EPNS) (2013-2017)

Finbar graduated from Oxford with a MA (Hons) in Modern History in 1983 before going on to study medicine at Bristol Medical School, graduating in 1990. He trained in paediatrics and paediatric neurology in Bristol, Bath, Birmingham, Toronto and Southampton. He trained in clinical epidemiology at the London School of Hygiene and Tropical Medicine and the MRC Environmental Epidemiology Unit in Southampton. He was awarded his MSc in Epidemiology in 1997 and PhD in 2002. Subsequently, he was Senior Clinical Research Fellow at the National Perinatal Epidemiology Unit, University of Oxford. Finbar was appointed Consultant Paediatric Neurologist in Bristol in 2003 before moving to Great Ormond Street Hospital in London in 2013.

Finbar’s research has been in the area of neuroepidemiology and clinical trials, specifically ininfantile epilepsies, tuberous sclerosis complex and stroke. He was Chief Investigator of the investigator-led International Collaborative Infantile Spasm Study (ICISS), the Metformin Tuberous Sclerosis Study (MiTS) and the Study of Outcome of Childhood Stroke (SOCS). He has also been UK Chief Investigator of the industry studies of Everolimus in Tuberous Sclerosis (EXIST Trials 1&3) and Epidiolex in Tuberous Sclerosis (GWPCARE6).

Read More

Scientific Advisory Board Members

Sapient Therapeutics Pipeline 2024

Get in touch

Please feel free to send us an email if you have any questions or would like to find out more.

Name(Required)

Operations (UK)

Sapient Therapeutics Ltd

6 Stratton Street, Mayfair, London, W1J 8LD, UK

Operations (Australia)

Sapient Therapeutics (Australia) Pty Ltd,

Level 7, 330 Collins Street, Melbourne VIC 3000